← Back to Screener
Organon & Co. (OGN)
Price$9.26
Favorite Metrics
Price vs S&P 500 (26W)-10.43%
Price vs S&P 500 (4W)43.91%
Market Capitalization$2.41B
P/E Ratio (Annual)12.89x
Indicated Dividend Yield (Annual)0.86%
All Metrics
P/CF (Annual)3.44x
Book Value / Share (Quarterly)$2.89
Indicated Dividend (Annual)$0.08
Revenue Growth (3Y)0.23%
Cash Flow / Share (Quarterly)$1.48
Payout Ratio (TTM)31.54%
Price vs S&P 500 (YTD)25.22%
Gross Margin (TTM)53.30%
Net Profit Margin (TTM)3.01%
EPS (TTM)$0.72
10-Day Avg Trading Volume11.27M
EPS Excl Extra (TTM)$0.72
Revenue Growth (5Y)-0.99%
EPS (Annual)$0.72
Dividend / Share (Annual)$0.34
ROI (Annual)1.99%
Gross Margin (Annual)53.30%
Net Profit Margin (5Y Avg)13.82%
Cash / Share (Quarterly)$2.21
P/E Basic Excl Extra (TTM)12.89x
Revenue Growth QoQ (YoY)-5.34%
EPS Growth (5Y)-39.07%
P/E Normalized (Annual)12.89x
ROA (Last FY)1.45%
Revenue Growth TTM (YoY)-2.92%
EBITD / Share (TTM)$4.22
ROE (5Y Avg)65.39%
Operating Margin (TTM)6.84%
Cash Flow / Share (Annual)$1.48
P/B Ratio3.21x
P/B Ratio (Quarterly)2.48x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)1.69x
Net Interest Coverage (TTM)2.24x
ROA (TTM)1.41%
EPS Growth QoQ (YoY)-55.59%
EV / EBITDA (TTM)9.54x
EPS Incl Extra (Annual)$0.72
Current Ratio (Annual)1.82x
Quick Ratio (Quarterly)1.23x
3-Month Avg Trading Volume5.56M
52-Week Price Return-16.73%
EV / Free Cash Flow (Annual)27.29x
P/E Incl Extra (TTM)12.89x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$-22.51
P/S Ratio (Annual)0.39x
Asset Turnover (Annual)0.48x
52-Week High$13.24
Operating Margin (5Y Avg)14.52%
EPS Excl Extra (Annual)$0.72
CapEx CAGR (5Y)4.38%
26-Week Price Return-3.54%
Quick Ratio (Annual)1.23x
13-Week Price Return6.44%
Total Debt / Equity (Annual)11.49x
Current Ratio (Quarterly)1.82x
Enterprise Value$10,480.523
Revenue / Share Growth (5Y)-1.58%
Asset Turnover (TTM)0.47x
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)2.13x
Pretax Margin (Annual)6.84%
Cash / Share (Annual)$2.21
3-Month Return Std Dev83.78%
Gross Margin (5Y Avg)59.43%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)-17.36%
EBITDA Interim CAGR (5Y)-47.59%
ROE (Last FY)24.87%
Net Interest Coverage (Annual)4.02x
EPS Basic Excl Extra (Annual)$0.72
P/FCF (TTM)5.94x
Receivables Turnover (TTM)4.62x
EV / Free Cash Flow (TTM)27.29x
Total Debt / Equity (Quarterly)11.49x
EPS Incl Extra (TTM)$0.72
Receivables Turnover (Annual)4.62x
ROI (TTM)1.96%
P/S Ratio (TTM)0.39x
Pretax Margin (5Y Avg)14.52%
Revenue / Share (Annual)$23.84
Tangible BV / Share (Annual)$-24.15
Forward P/E2.67x
Free OCF CAGR (5Y)-27.61%
Price vs S&P 500 (52W)-51.36%
P/E Ratio (TTM)12.89x
EPS Growth TTM (YoY)-78.50%
Year-to-Date Return29.15%
5-Day Price Return6.44%
EPS Normalized (Annual)$0.72
ROA (5Y Avg)7.51%
Net Profit Margin (Annual)3.01%
Month-to-Date Return54.59%
Cash Flow / Share (TTM)$3.18
EBITD / Share (Annual)$4.21
EPS Growth (3Y)-41.58%
Operating Margin (Annual)6.84%
LT Debt / Equity (Annual)11.47x
P/CF (TTM)3.44x
ROI (5Y Avg)24.38%
P/E Excl Extra (TTM)12.89x
LT Debt / Equity (Quarterly)11.47x
EPS Basic Excl Extra (TTM)$0.72
Payout Ratio (Annual)47.06%
P/B Ratio (Annual)2.48x
Dividend / Share (TTM)$0.34
Inventory Turnover (TTM)2.13x
Pretax Margin (TTM)6.84%
Book Value / Share (Annual)$2.89
Price vs S&P 500 (13W)4.06%
Net Margin Growth (5Y)-38.08%
Dividend Yield (TTM)3.65%
Beta0.98x
P/FCF (Annual)6.28x
Revenue / Share (TTM)$23.89
ROE (TTM)25.50%
52-Week Low$5.69
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.44
2.44
2.44
2.44
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
OGNOrganon & Co. | 0.39x | -2.92% | 53.30% | -39.07% | $9.26 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Organon & Co is a pharmaceutical company focused on women's health, biosimilars, and established brand medications. The majority of revenue comes from established brands, with geographic concentration in Europe and Canada, followed by the United States and Asia Pacific.